Effects of failure to enroll Part D beneficiaries

12 January 2009

The US Medicare Part D prescription drug benefit has failed to enroll millions of eligible US residents, despite their lack of alternative  coverage. The program has cost more than 30% less than originally  forecast, largely thanks to competition between private providers,  better-than-expected discounts for drugs from pharmaceutical firms and a  rise in the proportion of patients willing to switch to generic  compounds.

Representative Henry Waxman (Democrat, California) who will assume the  chairmanship of the US House of Representatives' Energy and Commerce  Committee in 2009, argues that the failure to enrol people on low  incomes has helped the image of a cost-effective federal government  program (Marketletters passim).

In Tennessee, an estimated 133,000 residents who qualify for the Part D  drug scheme have not done so, according to the Tennessean newspaper.  There are 49 stand-alone and 104 Medicare Advantage plans available in  the state, the latter providing comprehensive medical insurance  coverage. The cheapest drug-only deals cost $17.60 per month in  premiums.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight